The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) is a huge mover today! About 257,194 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 11.36% since April 4, 2016 and is uptrending. It has outperformed by 10.27% the S&P500.
The move comes after 5 months positive chart setup for the $1.50B company. It was reported on Nov, 4 by Barchart.com. We have $53.95 PT which if reached, will make NASDAQ:SAGE worth $465.00 million more.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 78% are positive. SAGE Therapeutics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, June 23. The stock has “Sell” rating given by Chardan Capital Markets on Tuesday, May 24. The firm has “Buy” rating given on Friday, March 11 by Lake Street. As per Wednesday, March 30, the company rating was initiated by Goldman Sachs. The rating was initiated by Raymond James with “Outperform” on Tuesday, September 13. The company was maintained on Thursday, September 3 by Leerink Swann. The company was initiated on Wednesday, June 29 by BMO Capital Markets. The rating was maintained by JP Morgan with “Buy” on Thursday, September 3.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in 2016 Q2. Its down 0.73, from 2.24 in 2016Q1. The ratio turned negative, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
The Israel-based Sphera Funds Management Limited has invested 0.54% in SAGE Therapeutics Inc (NASDAQ:SAGE). Kingdon Mgmt Ltd Liability Corp reported 190,100 shares or 0.31% of all its holdings. Alliancebernstein Ltd Partnership, a New York-based fund reported 1.05 million shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in the company for 569 shares. The Minnesota-based Ameriprise Fin has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Ladenburg Thalmann Financial Incorporated last reported 0% of its portfolio in the stock. Tiaa Cref Inv Management has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). The California-based Wells Fargo Mn has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Blackrock Fund Advisors holds 1.04M shares or 0.01% of its portfolio. J Goldman & Limited Partnership, a New York-based fund reported 46,500 shares. Vanguard Gp Inc accumulated 0% or 1.74 million shares. Jpmorgan Chase Company holds 1.08 million shares or 0.01% of its portfolio. The Massachusetts-based Putnam Invests Ltd Com has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Secor Advsrs Ltd Partnership accumulated 19,461 shares or 0.07% of the stock. Lazard Asset Lc has 57,300 shares for 0% of their US portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 insider purchases, and 5 selling transactions for $54.36 million net activity. Third Rock Ventures II – L.P. had sold 850,000 shares worth $26.56M. The insider IGUCHI KIMI sold $247,750. Another trade for 850,000 shares valued at $26.56 million was made by STARR KEVIN P on Monday, May 16. 22,000 shares were sold by Robichaud Albert, worth $880,000.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Nasdaq.com with their article: “Sage Therapeutics Becomes Oversold (SAGE)” published on November 03, 2016, Businesswire.com published: “Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides …” on November 03, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Prnewswire.com and their article: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016” published on September 27, 2016 as well as Marketwatch.com‘s news article titled: “Sage Therapeutics stock rises 12% after FDA designates drug a ‘breakthrough …” with publication date: September 06, 2016.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.